Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma (Q33346827)

26 July 2017

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma (English)

1 reference

26 July 2017

1 reference

1 reference

J F de Groot

1

1 reference

26 July 2017

M R Gilbert

2

1 reference

26 July 2017

K Aldape

3

1 reference

26 July 2017

K R Hess

4

1 reference

26 July 2017

T A Hanna

5

1 reference

26 July 2017

S Ictech

6

1 reference

26 July 2017

M D Groves

7

1 reference

26 July 2017

C Conrad

8

1 reference

26 July 2017

H Colman

9

1 reference

26 July 2017

V K Puduvalli

10

1 reference

26 July 2017

V Levin

11

1 reference

26 July 2017

W K A Yung

12

1 reference

26 July 2017

language of work or name

1 reference

26 June 2008

1 reference

Journal of Neuro-Oncology

26 July 2017

1 reference

26 July 2017

90

1 reference

26 July 2017

89-97

1 reference

26 July 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-008-9637-y

26 July 2017

0 references

cites work

Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Comparison of the cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Amplified cellular oncogenes in neoplasms of the human central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Biomarkers to predict response to epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Intravenous carboplatin for recurrent gliomas. A dose-escalating phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

EGFR mutations and sensitivity to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Function of aberrant EGFR in malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Structural alterations of the epidermal growth factor receptor gene in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-008-9637-Y

Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774).

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6059769

Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6059769

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6059769

Response criteria for phase II studies of supratentorial malignant glioma

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6059769

Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group stud

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18581057

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18581057

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18581057

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-008-9637-Y

1 reference

Dimensions Publication ID

26 July 2017

0 references

0 references

1 reference